ELTX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Elicio Therapeutics Inc (ELTX) is a good buy for a beginner investor with a long-term focus and $50,000-$100,000 available for investment. The stock shows strong technical momentum, positive analyst sentiment, and promising clinical developments in its pipeline. Despite weak financials, the company's innovative technology and potential in addressing high-need cancer indications make it a compelling long-term opportunity.
The stock is in a strong bullish trend with MACD histogram at 0.168 (positively expanding), RSI at 83.131 (overbought), and bullish moving averages (SMA_5 > SMA_20 > SMA_200). Key resistance levels are R1: 12.369 and R2: 13.085, while support levels are S1: 10.05 and S2: 9.334. The stock closed at $12.8, above the pivot level of $11.209, indicating strong upward momentum.
Analysts are bullish with multiple Buy ratings and increased price targets (up to $20).
Promising clinical outcomes for ELI-002 in mKRAS-positive pancreatic and colorectal cancers.
Innovative Amphiphile technology for faster and cost-effective immunotherapy.
Positive sentiment in options data with low put-call ratios and high call volume.
Weak financial performance with declining net income (-44.89% YoY) and EPS (-51.46% YoY).
Overbought RSI (83.
may indicate a potential short-term pullback.
In Q4 2025, the company reported no revenue growth (0% YoY), a net income loss of -$7.72M (-44.89% YoY), and a significant EPS drop to -0.5 (-51.46% YoY). Gross margin remained at 0%.
Analysts are highly positive on ELTX. Ladenburg initiated a Buy rating with a $20 price target, citing the company's potential to set a new standard of care in pancreatic cancer. H.C. Wainwright raised its price target to $17 from $13, increasing the probability of success for ELI-002 to 50%. Rodman & Renshaw also issued a Buy rating with a $17 price target, highlighting ELI-002 as a paradigm shift in mKRAS immunotherapy.
